Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

Siegel, 2014, Cancer statistics, 2014, CA Cancer J Clin, 64, 9, 10.3322/caac.21208 Falci, 2009, Treatment of prostate cancer in unfit senior adult patients, Cancer Treat Rev, 35, 522, 10.1016/j.ctrv.2009.04.014 O'Donnell, 2004, Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer, Br J Cancer, 90, 2317, 10.1038/sj.bjc.6601879 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Heeringa, 2006, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, Eur Heart J, 27, 949, 10.1093/eurheartj/ehi825 Sternberg, 2013, Treatment patterns and characteristics of European patients with castration-resistant prostate cancer, BMC Urol, 13, 58, 10.1186/1471-2490-13-58 Procopio, 2015, Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors, Am J Clin Oncol, 38, 479, 10.1097/COC.0b013e3182a790ce Laukkanen, 2005, Left atrium size and the risk of cardiovascular death in middle-aged men, Arch Intern Med, 165, 1788, 10.1001/archinte.165.15.1788 Bouzas-Mosquera, 2011, Left atrial size and risk for all-cause mortality and ischemic stroke, CMAJ, 183, E657, 10.1503/cmaj.091688 Benjamin, 1995, Left atrial size and the risk of stroke and death: the Framingham Heart Study, Circulation, 92, 835, 10.1161/01.CIR.92.4.835 Allessie, 2002, Electrical, contractile and structural remodeling during atrial fibrillation, Cardiovasc Res, 54, 230, 10.1016/S0008-6363(02)00258-4